Skip to main content

Advertisement

SpringerLink
Log in

Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Inflammation is known to play an important role in the biology of metastatic pancreatic adenocarcinoma (mPDAC), and systemic inflammatory response (SIR) is reported to be closely related to outcome in mPDAC. The aim of the present paper is to assess the prognostic performance of SIR-related variables in patients with mPDAC receiving cytotoxic chemotherapy. Data of patients with mPDAC, who were registered in the database of the division of Medical Oncology of the G. Borea Hospital in Sanremo, were retrospectively collected. Three SIR-related variables were calculated. Univariate and multivariate analyses have been performed by Cox regression, and every SIR-related variable was added to the Cox model. After univariate analyses, four variables reported a significant relationship with overall survival (OS) and were included in a Cox model. Two of the three SIR-related variables were related with OS in the bivariate analyses, and maintained their independent prognostic effect when added to the previous Cox model in multivariate analysis. These variables were two scores, such as neutrophil-platelet score (NPS; HR 2.144, CIs 1.392–3.300) and tri-linear peripheric blood cell score (TRIS; HR 1.813, CIs 1.331–2.468). It appears that the second-generation inflammation-related variables are more effective in predicting prognosis of patients with mPDAC receiving chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malvezzi M, Cairoli G, Bertuccio P, et al. European cancer mortality predictiona for the year 2016 with focus on leukemias. Ann Oncol. 2016;27:725–31.

    Article  CAS  Google Scholar 

  2. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:18–48.

    Article  Google Scholar 

  3. Goldstein D, Hassan El-Maraghi R, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer. Long-term suvival from a phase III trial. J Natl Cancer Inst. 2015;107:dju413.

    Article  Google Scholar 

  4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  Google Scholar 

  5. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells, in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation on the Th2 cytokine interlaukin-13. Cancer Immunol Immunother. 2011;60:1419–30.

    Article  CAS  Google Scholar 

  6. Ahmad J, Grimes N, Farid S, Morris-Stiff G. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. Hepatobil Pancreat Dis Int. 2014;13:474–81.

    Article  Google Scholar 

  7. Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science. 2016;346:1234–8.

    Article  Google Scholar 

  8. Tao L, Zhang L, Peng Y, et al. Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma. Medicine. 2016;95:39.

    Google Scholar 

  9. Gao Y, Wang W-J, Zhi Q, et al. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8:88835–44.

    PubMed  PubMed Central  Google Scholar 

  10. Suzuki R, Takagi T, Hikichi T, et al. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016;11:3441–5.

    Article  CAS  Google Scholar 

  11. Xue P, Hang J, Huang W, et al. Validation of lymphocyte-to monocyte ratio as a prognostic factor in advanced pancreatic cancer: an East asian cohort study of 2 country. Pancreas. 2017;46:1011–7.

    Article  Google Scholar 

  12. Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J. 2014; 676 – 82.

    Article  CAS  Google Scholar 

  13. Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels. Ann Surg. 2018. https://doi.org/10.1097/SLA.0000000000002660.

    Article  PubMed  Google Scholar 

  14. Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122:2158–67.

    Article  Google Scholar 

  15. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109:401–7.

    Article  CAS  Google Scholar 

  16. Watt DG, Proctor MJ, Park JH, Horgan PG, McMillan DC. The neutrophil-platelet score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS ONE. 2015;10:e0142159.

    Article  Google Scholar 

  17. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matriian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.

    Article  CAS  Google Scholar 

  18. Papadoniou N, Kosmas C, Gennatas K, et al. Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res. 2008;28:543–50.

    PubMed  Google Scholar 

  19. Tao L, Yuan C, Ma Z, Jiang B, Xiu D. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manage Res. 2017;9:471–79.

    Article  Google Scholar 

  20. Oweira H, Petrausch U, Helbling D, et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 2017;23:1872–80.

    Article  Google Scholar 

  21. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and post-operative recurrence. World J Surg. 2017;41:2858–66.

    Article  Google Scholar 

  22. Wangjam T, Zhang Z, Zhou XC, et al. Resected pancreatic ductal adenocarcinoma with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015;6:36903–10.

    Article  Google Scholar 

  23. Downs-Canner S, Zenati M, Boone BA, et al. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol. 2015;112:80–5.

    Article  Google Scholar 

  24. Tas F, Karabulut S, Ciftici R, et al. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol. 2014;73:1163–71.

    Article  CAS  Google Scholar 

  25. Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–9.

    Article  CAS  Google Scholar 

  26. Tsavaris N, Kosmas C, Papadoniou N, et al. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother. 2009;21:673–80.

    Article  CAS  Google Scholar 

  27. Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 + T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60:1269–79.

    Article  CAS  Google Scholar 

  28. Annels NE, Shaw VE, Gabitass RF, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother. 2014;63:175–83.

    Article  CAS  Google Scholar 

  29. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

    Article  CAS  Google Scholar 

  30. Cheng H, Long F, Jaiswar M, Yang L, Wang C, Zhou Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis. Sci Rep. 2015;5:11026.

    Article  CAS  Google Scholar 

  31. Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22:670–6.

    Article  Google Scholar 

  32. Stotz M, Gerger A, Eisner F, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416–21.

    Article  CAS  Google Scholar 

  33. Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HBP. 2015;17:285–91.

    Google Scholar 

  34. Miao C, Zhu S, Pan H, et al. Combined neutrophil-platelet score and hemoglobin level predict survival in esophageal squamous cell carcinoma patients treated with chemotadiotherapy. Oncotarget. 2017;8:87971–9.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, G. Borea Hospital, Via G. Borea n. 56, 18038, Sanremo, Imperia, Italy

    Giuseppe A. Colloca, Antonella Venturino & Domenico Guarneri

Authors
  1. Giuseppe A. Colloca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonella Venturino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Guarneri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe A. Colloca.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Regione Liguria research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 27 KB)

Supplementary material 2 (DOC 43 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colloca, G.A., Venturino, A. & Guarneri, D. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. Med Oncol 35, 158 (2018). https://doi.org/10.1007/s12032-018-1219-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1219-z

Keywords

Search

Navigation